Nitric oxide-releasing compounds for the treatment of lung infections

Drug Discov Today. 2021 Feb;26(2):542-550. doi: 10.1016/j.drudis.2020.10.027. Epub 2020 Nov 9.

Abstract

The spread of acquired drug resistance and of microorganisms naturally resistant to antibiotics is a major threat to global health, leading to an urgent need for novel antimicrobial compounds. Exogenous nitric oxide (NO) represents an attractive and promising antimicrobial approach, showing both bactericidal and biofilm dispersal activities. Numerous studies have been performed to develop NO donor scaffolds, including small molecules, macromolecular compounds, nanoparticles (NPs), and polymeric materials. This approach has resulted in successful outcomes, with some NO-releasing compounds entering clinical practice. In this review, we highlight the importance of this strategy, with a focus on lung infections.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Anti-Bacterial Agents / pharmacology*
  • Biofilms / drug effects
  • Drug Resistance, Bacterial
  • Humans
  • Lung Diseases / drug therapy
  • Lung Diseases / microbiology
  • Nanoparticles
  • Nitric Oxide / metabolism*
  • Polymers / chemistry
  • Respiratory Tract Infections / drug therapy*
  • Respiratory Tract Infections / microbiology

Substances

  • Anti-Bacterial Agents
  • Polymers
  • Nitric Oxide